Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Case Report

A Rare Combination of Breast, and Thyroid Carcinoma, with Superadded COVID-19 Infection in Mother: Struggle of a Doctor as a Daughter – Case Report

Author(s): Naina Kumar*

Volume 20, Issue 3, 2024

Published on: 03 July, 2023

Article ID: e070623217742 Pages: 5

DOI: 10.2174/1573404820666230607112810

Price: $65

Abstract

Introduction: COVID-19 pandemic has severely affected the diagnosis and management of cancer patients to a large extent, with many patients being diagnosed at a later stage, and many are not able to get appropriate treatment. Furthermore, cancer patients are more prone to suffer from severe COVID-19 infection and its associated morbidity and mortality. Breast cancer is one of the commonest cancers affecting women worldwide and its number is projected to increase sharply in the post- COVID-19 era due to a serious fall in screening modalities, as patients stopped reporting to the hospital because of lockdown, movement restrictions, and fear of contracting the infection.

Case Presentation: The present case report briefs a mother's sufferings and the impact it has on a daughter who is a doctor herself. It reports a rare combination of two primaries in the breast and thyroid in an asymptomatic patient with a rare mutation of the BLM gene detected incidentally. The patient was successfully operated on for stage IB ductal carcinoma breast with hemithyroidectomy and was put on chemotherapy with Cyclophosphamide 1000mg (600mg/m2) and Doxorubicin 100 mg (60mg/m2) per cycle on day one every fortnightly followed by four cycles of Paclitaxel 175mg/m2 every fortnightly. After the second cycle, the patient developed severe neutropenia and COVID-19 infection with atypical symptoms that severely involved her lungs, leading to the loss of the patient.

Conclusion: With the onset of the COVID-19 pandemic, thousands of cancer patients have lost their lives, not due to cancer directly but due to failed early detection, treatment, loss of follow-up, and superadded severe COVID-19 infection.

Graphical Abstract

[1]
Wasim, U.; Tahir, M.J.; Siddiqi, A.R.; Jabbar, A.; Ullah, I. The impact of the COVID‐19 pandemic on impending cancer deaths due to delays in diagnosis in the UK. J. Med. Virol., 2022, 94(1), 20-21.
[http://dx.doi.org/10.1002/jmv.27305] [PMID: 34453760]
[2]
Alkatout, I.; Biebl, M.; Momenimovahed, Z.; Giovannucci, E.; Hadavandsiri, F.; Salehiniya, H.; Allahqoli, L. Has COVID-19 affected cancer screening programs? A systematic review. Front. Oncol., 2021, 11, 675038.
[http://dx.doi.org/10.3389/fonc.2021.675038] [PMID: 34079764]
[3]
Lai, A.G.; Pasea, L.; Banerjee, A.; Hall, G.; Denaxas, S.; Chang, W.H.; Katsoulis, M.; Williams, B.; Pillay, D.; Noursadeghi, M.; Linch, D.; Hughes, D.; Forster, M.D.; Turnbull, C.; Fitzpatrick, N.K.; Boyd, K.; Foster, G.R.; Enver, T.; Nafilyan, V.; Humberstone, B.; Neal, R.D.; Cooper, M.; Jones, M.; Pritchard-Jones, K.; Sullivan, R.; Davie, C.; Lawler, M.; Hemingway, H. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: Near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open, 2020, 10(11), e043828.
[http://dx.doi.org/10.1136/bmjopen-2020-043828] [PMID: 33203640]
[4]
Alagoz, O.; Lowry, K.P.; Kurian, A.W.; Mandelblatt, J.S.; Ergun, M.A.; Huang, H.; Lee, S.J.; Schechter, C.B.; Tosteson, A.N.A.; Miglioretti, D.L.; Trentham-Dietz, A.; Nyante, S.J.; Kerlikowske, K.; Sprague, B.L.; Stout, N.K. Impact of the COVID-19 pandemic on breast cancer mortality in the US: Estimates from collaborative simulation modeling. J. Natl. Cancer Inst., 2021, 113(11), 1484-1494.
[http://dx.doi.org/10.1093/jnci/djab097] [PMID: 34258611]
[5]
Kluźniak, W.; Wokołorczyk, D.; Rusak, B.; Huzarski, T.; Kashyap, A.; Stempa, K.; Rudnicka, H.; Jakubowska, A.; Szwiec, M.; Morawska, S.; Gliniewicz, K.; Mordak, K.; Stawicka, M.; Jarkiewicz-Tretyn, J.; Cechowska, M.; Domagała, P.; Dębniak, T.; Lener, M.; Gronwald, J.; Lubiński, J.; Narod, S.A.; Akbari, M.R.; Cybulski, C. Inherited variants in BLM and the risk and clinical characteristics of breast cancer. Cancers, 2019, 11(10), 1548.
[http://dx.doi.org/10.3390/cancers11101548] [PMID: 31614901]
[6]
Mousavi, S.A.; Rostami, T.; Kiumarsi, A.; Rad, S.; Rostami, M.; Motamedi, F.; Gandomi-Mohammadabadi, A.; Mirhosseini, A. COVID-19 and cancer: A comparative case series. Cancer Treat. Res. Commun., 2021, 27, 100339.
[http://dx.doi.org/10.1016/j.ctarc.2021.100339] [PMID: 33618150]
[7]
Lee, L.Y.W.; Cazier, J.B.; Angelis, V.; Arnold, R.; Bisht, V.; Campton, N.A.; Chackathayil, J.; Cheng, V.W.T.; Curley, H.M.; Fittall, M.W.; Freeman-Mills, L.; Gennatas, S.; Goel, A.; Hartley, S.; Hughes, D.J.; Kerr, D.; Lee, A.J.X.; Lee, R.J.; McGrath, S.E.; Middleton, C.P.; Murugaesu, N.; Newsom-Davis, T.; Okines, A.F.C.; Olsson-Brown, A.C.; Palles, C.; Pan, Y.; Pettengell, R.; Powles, T.; Protheroe, E.A.; Purshouse, K.; Sharma-Oates, A.; Sivakumar, S.; Smith, A.J.; Starkey, T.; Turnbull, C.D.; Várnai, C.; Yousaf, N.; Kerr, R.; Middleton, G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet, 2020, 395(10241), 1919-1926.
[http://dx.doi.org/10.1016/S0140-6736(20)31173-9] [PMID: 32473682]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy